Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, will provide student sponsorship for a second year to the Future of Hearing Healthcare Conference, which will allow up to 75 audiology graduate students to attend the event at no cost.
The grant is open to any students currently pursuing a graduate-level degree (Master’s or Doctorate) in Audiology or related discipline.
The virtual conference, hosted by Hearing Health & Technology Matters, will take place over 3 days, from May 24th to May 26th, with a focus on the developments and technologies shaping hearing healthcare over the coming decade.
Kevin Franck, PhD, SVP of Stategic Marketing and New Product Planning, will be co-presenting a session during the conference alongside Frequency’s Chief Development Officer, Carl LeBel, PhD: “Potential New Therapies and Clinical Trial Opportunities for Adult-Onset Acquired Sensorineural Hearing Loss”
.
Future of Hearing Healthcare Conference
.
Attendees participating in the event can earn valuable CEUs (up to 12 contact hours) from leading experts in clinical audiology, neuroscience, hearing aids, consumer technology and more.
Among the topics being addressed during the conference:
- Hair Cell Regeneration
- Clinical and Practice Differentiation
- Forensic Audiology
- Haptic Tech for Hearing Loss
- Balance & Vestibular Care
- Assistive Technologies
- Cerumen Removal
- Going Beyond the Hearing Aid
Attendees will have access to the sessions for up to 30 days. Individuals interested to learn more about the event, please visit: https://hearinghealthmatters.org/fhh-conference/
Tickets are available at an early-bird rate of $99, if purchased by May 6th. Tickets are available here: https://www.accelevents.com/e/futureofhearinghealthcare22
The first 100 registrants will also receive a free copy of Brian Taylor’s upcoming book, Indispensable: What Four Acclaimed Late Audiologists Can Teach Us About the Value of Customization in the Era of Self-directed Care, set to be released in late May 2022.
.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells to restore lost function. Frequency’s hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for SNHL. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss. Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, the Scripps Research Institute and Cambridge Enterprises Limited.
About HHTM
Hearing Health & Technology Matters (HHTM) is an organization dedicated to bridging the knowledge gaps in treating hearing loss by providing timely information and lively insights to anyone who cares about hearing loss. Readers and contributors are drawn from many sectors of the hearing field, including prctitioners, researchers, manufacturers, educators, and, importantly, consumers with hearing loss and those who love them. By involving all these groups, we hope to bridge the gaps in knowledge that so often divide them. To learn more, visit HearingHealthMatters.org.
